These results showed that deguelin possessed antitumor effect by targeting Akt in dual axis such as EGFR and IGF1R signaling pathways and suggested that it provides an applicable therapeutic strategy for HNSCC patients. This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.